| General Information | |
|---|---|
| ZINC ID | ZINC000095572538 |
| Molecular Weight (Da) | 574 |
| SMILES | C[C@@H](O)[C@H](N/C(=N/S(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](c2ccccc2)C(c2ccc(Cl)cc2)=N1)C(N)=O |
| Molecular Formula | C26Cl2N5O4S1 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 146.131 |
| HBA | 6 |
| HBD | 2 |
| Rotatable Bonds | 9 |
| Heavy Atoms | 38 |
| LogP | 4.167 |
| Activity (Ki) in nM | 7.0795 |
| Polar Surface Area (PSA) | 145.83 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.034 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 18 |
| Fraction csp3 | 0.19 |
| Ilogp | 3.24 |
| Xlogp3 | 4.09 |
| Wlogp | 3.69 |
| Mlogp | 2.87 |
| Silicos-it log p | 3.55 |
| Consensus log p | 3.49 |
| Esol log s | -5.73 |
| Esol solubility (mg/ml) | 0.00106 |
| Esol solubility (mol/l) | 0.00000184 |
| Esol class | Moderately |
| Ali log s | -6.86 |
| Ali solubility (mg/ml) | 0.0000797 |
| Ali solubility (mol/l) | 0.00000013 |
| Ali class | Poorly sol |
| Silicos-it logsw | -7.93 |
| Silicos-it solubility (mg/ml) | 0.0000067 |
| Silicos-it solubility (mol/l) | 1.17E-08 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -6.9 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 2 |
| Veber number of violations | 1 |
| Egan number of violations | 1 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 2 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 5.34 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -3.623 |
| Logd | 1.437 |
| Logp | 3.348 |
| F (20%) | 0.002 |
| F (30%) | 0.001 |
| Mdck | - |
| Ppb | 98.14% |
| Vdss | 0.655 |
| Fu | 4.45% |
| Cyp1a2-inh | 0.114 |
| Cyp1a2-sub | 0.719 |
| Cyp2c19-inh | 0.485 |
| Cyp2c19-sub | 0.87 |
| Cl | 0.536 |
| T12 | 0.059 |
| H-ht | 0.884 |
| Dili | 0.987 |
| Roa | 0.357 |
| Fdamdd | 0.881 |
| Skinsen | 0.055 |
| Ec | 0.003 |
| Ei | 0.004 |
| Respiratory | 0.305 |
| Bcf | 0.388 |
| Igc50 | 4.718 |
| Lc50 | 5.525 |
| Lc50dm | 5.23 |
| Nr-ar | 0.004 |
| Nr-ar-lbd | 0.048 |
| Nr-ahr | 0.093 |
| Nr-aromatase | 0.107 |
| Nr-er | 0.418 |
| Nr-er-lbd | 0.007 |
| Nr-ppar-gamma | 0.1 |
| Sr-are | 0.385 |
| Sr-atad5 | 0.006 |
| Sr-hse | 0.003 |
| Sr-mmp | 0.893 |
| Sr-p53 | 0.059 |
| Vol | 531.465 |
| Dense | 1.078 |
| Flex | 0.333 |
| Nstereo | 3 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 2 |
| Acute aquatic toxicity | - |
| Toxicophores | 3 |
| Qed | 0.225 |
| Synth | 3.9 |
| Fsp3 | 0.192 |
| Mce-18 | 84.484 |
| Natural product-likeness | -0.566 |
| Alarm nmr | 1 |
| Bms | 1 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |